Voclosporin Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death: A Post-Hoc Analysis of the AURORA 1 Phase 3 Study (EULAR 2026) - Mar 18, 2026 - Abstract #POS0686; B.1271; K186; Pres time: Jun 4, 2026; 09:30 AM - 10:30 AM; Location: Poster View; P3 | "Methods In AURORA 1, patients were randomized to either voclosporin (23.7 mg) or placebo twice daily in combination with mycophenolate mofetil (target 2 g/day) and low-dose glucocorticoids (target ≤2.5 mg/day by Week 16). The probability of worsening eGFR was similar in both treatment arms. Conclusions This analysis from the AURORA 1 Phase 3 study demonstrates that, in addition to significant improvements in CRR, treatment with voclosporin is also associated with a statistically significant and clinically meaningful reduction in the risk of Renal-Related Event or Death, reinforcing voclosporin's favorable efficacy and safety profile."
P3 data • Retrospective data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease
|
|
Amit Saxena1; Ellen M Ginzler2; Cristina Arriens3, 4; Dawn Caster 5; Juanita Romero-Diaz6; Keisha Gibson7, 8; Joshua Kaplan9; Sandra Navarra10, 11; Samir Parikh12; Greg Keenan13; Stew Kroll13; Brad H. Rovin12
|